2 documents found, page 1 of 1
Screening a Targeted Panel of Genes by Next-Generation Sequencing Improves Risk...
Matos, S; Bernardo, P; Esteves, S; Botelho de Sousa, A; Lemos, M; Ribeiro, P; Silva, M; Nunes, A; Lobato, J; Frade, MJ; Gomes da Silva, M; Chacim, SAlthough mutation profiling of defined genes is recommended for classification of acute myeloid leukemia (AML) patients, screening of targeted gene panels using next-generation sequencing (NGS) is not always routinely used as standard of care. The objective of this study was to prospectively assess whether extended molecular monitoring using NGS adds clinical value for risk assessment in real-world AML patients...
Lenalidomide is effective and safe for the treatment of patients with relapsed ...
João, C; Freitas, J; Gomes, F; Geraldes, C; Coelho, I; Neves, M; Lúcio, P; Esteves, S; Esteves, GPatients with multiple myeloma (MM) and severe renal impairment (SRI) have shorter survival than MM patients without renal failure. Although lenalidomide is a highly active drug, this immunomodulatory agent is frequently neglected in this context due to its predominant renal clearance and, consequently, an increased risk of toxicity. This risk might be overcome with the proper lenalidomide dose adjustment to re...